Skip Navigation

Journal of Antimicrobial Chemotherapy 2006 58(3):693-696; doi:10.1093/jac/dkl305
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Stass, H.
Right arrow Articles by Vestweber, K.-H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stass, H.
Right arrow Articles by Vestweber, K.-H.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Pharmacokinetics and peritoneal penetration of moxifloxacin in peritonitis

H. Stass1,*, A. D. Rink2, H. Delesen1, D. Kubitza1 and K.-H. Vestweber2

1 Pharma Research Centre Bayer AG, Wuppertal, Germany 2 Department of General Surgery, Leverkusen General Hospital Leverkusen, Germany

Received 3 April 2006; returned 15 May 2006; revised 21 June 2006; accepted 4 July 2006


*Corresponding author. Institute of Clinical Pharmacology, Bayer HealthCare AG, Aprather Weg, Building 470, D-42096 Wuppertal, Germany. Tel: +49-202-364289; Fax: +49-202-368180; E-mail: Heino.stass{at}bayerhealthcare.com

Objectives: To investigate the penetration of moxifloxacin into peritoneal exudate in patients with complicated intra-abdominal infections (cIAIs).

Patients and methods: Patients (n = 10) with evidence of peritonitis who required surgery with drainage of the abdominal cavity received a single intravenous infusion of moxifloxacin, 400 mg, over 1 h. Plasma and peritoneal exudate samples were obtained over 24 h, and moxifloxacin concentrations were measured by HPLC with fluorescence detection.

Results: Plasma moxifloxacin concentrations decreased from a geometric mean of 3.61 mg/L at 1 h to 0.36 mg/L at 24 h. Concentrations in peritoneal exudate were highest 2 h after the start of the infusion, reaching a geometric mean of 3.32 mg/L, and declined to a geometric mean of 0.69 mg/L at 24 h. The exudate/plasma concentration ratio rose from 1.45 at 2 h to 1.91 at 24 h; the 95% confidence intervals for the ratio excluded unity at all time points, suggesting that moxifloxacin penetrates and accumulates in peritoneal exudate. The area under the concentration–time curve (AUC) tended to be greater in exudate; the time to peak concentrations (Tmax) was longer in exudate than in plasma, as were half-life and mean residence time (MRT).

Conclusions: Following intravenous administration, moxifloxacin penetrated peritoneal exudate in patients with peritonitis, achieving and maintaining concentrations that exceed the MICs for pathogens commonly isolated in cIAIs. These findings support the clinical use of moxifloxacin as treatment for cIAIs.

Keywords: ascitic fluid , complicated intra-abdominal infections , peritoneal cavity , tissue distribution


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
pdiHome page
C. Skalioti, T. Tsaganos, D. Stamatiadis, E. J. Giamarellos-Bourboulis, J. Boletis, and K. Kanellakopoulou
PHARMACOKINETICS OF MOXIFLOXACIN IN PATIENTS UNDERGOING CONTINUOUS AMBULATORY PERITONEAL DIALYSIS
Perit. Dial. Int., September 1, 2009; 29(5): 575 - 579.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.